Comment on “Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery”, by Yang WC et al.

We read with great interest the article from Yang et al. named "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery" [1]. In this large retrospective review of 147 patients undergoing stereotactic radiosurgery (SRS) for brain metastasis (BM) of non-small cell lung cancer (NSCLC), the authors were able to conclude that the presence of an Epidermal Growth Factor Receptor mutation (EGFR) was associated with better outcomes compared to wild type (wt) EGFR.

http://ift.tt/2kyIpPU